Gamida Cell Ltd. Signs Collaboration Agreement With Biologics Delivery Systems Group
The randomized, controlled multi-center Phase I/II clinical trial, due to start in Q4 2008 in Israel, will evaluate the safety and efficacy of Gamida Cell’s CardioCure in 48 post-MI patients. CardioCure will be injected directly into the myocardium using the latest generation of Biologics Delivery Systems’ NOGA® Cardiac Navigation System and MyoStar® Injection Catheter.
"The NOGA® XP Cardiac Navigation System is a highly sophisticated and accurate electro-guided methodology, which creates precise, 3-dimensional images of the heart. This will enable us to identify damaged myocardial tissue and accurately deliver the CardioCure injections into the relevant area in order to assist with functional restoration of the damaged heart," said Professor Ran Kornowski, Director of Interventional Cardiology and Cardiac Catheterization Laboratories at the Rabin Medical Center and a leading principal investigator in the Gamida Cell CardioCure clinical study.
Pre-clinical results demonstrate that CardioCure may offer a better therapeutic alternative to existing treatments. The data indicate that it may prevent or lessen some of the damage caused to the heart muscle as a result of a heart attack.
“More than one million new patients with heart attacks are treated annually in the United States alone, representing a multi-billion dollar market opportunity. The supply commitment today by Biologics Delivery Systems Group validates the significance of the CardioCure program and its potential as a therapeutic treatment for this very large patient population,” said Gamida Cell CEO Dr. Yael Margolin.
About Gamida Cell
Gamida Cell Ltd. is a world leader in stem cell expansion technologies and therapeutic products. The company is developing a pipeline of cell therapeutics to effectively treat debilitating and often fatal illnesses such as cancer, cardiac disease and peripheral vascular disease. Gamida Cell’s therapeutic candidates contain adult stem cells, selected from non-controversial sources such as umbilical cord blood and bone marrow, and which are enriched in culture using the company’s proprietary technologies. The company is dedicated to making a significant difference in the clinical practice of modern medicine by first creating, then tapping the regeneration power of an ample body of therapeutic stem cells. Current shareholders include Elbit Imaging, Biomedical Investments, IHCV, Teva Pharmaceutical Industries (NASDAQ:TEVA - News), Denali Ventures, and Auriga Ventures. For additional information please visit: www.gamida-cell.com.
Contact:
Gamida Cell Ltd. Marjie Hadad, +972-54-536-5220 marjie@gamida-cell.com
Source: Gamida Cell Ltd.